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Introduction: Magistral formulas (MF) are prepared by the pharmacist for a given patient 
according to a prescription and following technical and scientific compounding standards. MF 
are often used in weight loss regimens and contain blends of drugs (D) and plant (P) extracts. 
Associations potentiate interactions and related adverse effects, compromising effectiveness 
and risking the patient´s health (1,2). Thus, the purpose of this work was to give an overview of 
MF intended for slimming, prescribed by doctors, in a perspective of efficacy and safety. 
Materials and Methods: Slimming MF (prescribed to overweight women, as hard gelatine 
capsules, once or twice daily) were analyzed in terms of labelled drug/bioactive composition and 
dosage, therapeutic indication/claim, recommended daily dose (RDD), side effects/interactions 
and contraindications. Written consent for data use was obtained from patients.  
Results: MF did not contain unlawful ingredients (3); these were used mostly in sub therapeutic 
doses (Table 1). Weight loss is a result of (a) side effect of D-III/IV (off-label use), (b) water loss 
due to therapeutic action (D-I/IX and P-V/VII/VIII), or (c) claimed appetite reduction (P-VI/X/XI).  
 
 
Active ingredient (AI) MF1 MF2 MF3 MF4 MF5 MF6 MF7 
Main therapeutic  
indication / claim 
Usual posology in 
major pathology 
Furosemide 
I
 20 25  18 18 30  Diuretic 20-80/120 mg/day 
Chlordiazepoxide 
II
 8 8  8 8 10  Anxiolytic 30 mg (3 times/day) 
Bupropion 
III
 120 100  140 150 130  Antidepressant 150 mg (2 times/day) 
Metformine 
IV
 280  250 300 300 260  Antidiabetic
  
500 mg (2/3 times/day)
 
Artichoke 
V 110 400      Laxative 500 mg/day * 
Bitter orange (Citrus aurantium)
 VI
 150   200 200 200 200 Appetite reducer 50-100 mg/day * 
Centella asiatica L.
 VII
  400 400    750 Anti-cellulite, venotonic 60-120 mg/day * 
Cascara Sagrada (R. purshiana) 
VIII
  100  130  120  Laxative 150-325 mg/day * 
Phenolphthalein 
IX
 65 100   90 85  Laxative 30-200 mg/day 
Glucomannan (A. konjac) 
X
       500 Appetite reducer 1000-13000 mg/day* 
Slimalluma (Caralluma fimbriata)
 XI
  300 250     Appetite reducer
 
500 mg (2 times/day) * 
  Table 1. MF labels composition and dose (mg); roman superscripts identify the substance in the text. *RDD not well established 
 
Discussion and Conclusions: Off-label uses of drugs and efficacy of sub therapeutic doses 
are questionable. D-II,III present risk of abuse and dependence. Combination of laxatives (MF 
1,2 and 6) is not recommended, increasing the chances of electrolyte imbalance and dehydra-
tion, and reducing absorption of ansa diuretics. Clinical data to support the claims and posology 
of botanicals is scarce and contradictory; moreover, potential side effects/interactions are at 
times unknown and adulteration/contamination is a risk. Of note is the potential for interaction of 
P-V (inhibiting several isoenzymes of CYP450) and the association of D-I/P-V may cause 
hypovolemia and hypocaliemia. Even if no additional interactions were found between 
molecules, combinations may increase the risk of adverse events. Severe/fatal interactions may 
occur with other drugs (e.g. D-II + opioids; D-III + MAO inhibitors), so knowledge of patient's 
clinical history and related medication is of the utmost importance, when prescribing and 
counselling. Indeed, evaluation of safety and efficacy of MF is a shared responsability of doctor 
and pharmacist and requires robust scientific data, especialy regarding botanicals. Slimming 
medication alone, without lifestyle changes, is not effective in the long term and may be risky. 
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